Ovarian Cancer - Pipeline Review, H2 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Ovarian Cancer - Pipeline Review, H2 2016" report to their offering.

Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, changes in bowel habits, such as constipation, loss of appetite and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy and radiation therapy.

This report provides comprehensive information on the therapeutic development for Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ovarian Cancer and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Mentioned:

  • AbbVie Inc
  • AbGenomics International Inc
  • Acetylon Pharmaceuticals Inc
  • Adaptimmune Therapeutics Plc
  • Adgero Biopharmaceuticals Inc
  • Aduro BioTech Inc
  • Advanced Accelerator Applications SA
  • Commence Bio Inc
  • Compliment Corp
  • Corcept Therapeutics Inc
  • Critical Outcome Technologies Inc
  • CTI BioPharma Corp
  • Cyclacel Pharmaceuticals Inc
  • Deciphera Pharmaceuticals LLC
  • DEKK-TEC Inc
  • DelMar Pharmaceuticals Inc
  • Dr. Reddy's Laboratories Ltd
  • Ecrins Therapeutics SAS
  • EirGenix Inc
  • Eisai Co Ltd
  • Eli Lilly and Company
  • (200+ Others)

Key Topics Covered:

  1. Introduction
  2. Ovarian Cancer Overview
  3. Therapeutics Development
  4. Pipeline Products for Ovarian Cancer - Overview
  5. Pipeline Products for Ovarian Cancer - Comparative Analysis
  6. Ovarian Cancer - Therapeutics under Development by Companies
  7. Ovarian Cancer - Therapeutics under Investigation by Universities/Institutes
  8. Ovarian Cancer - Pipeline Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Ovarian Cancer - Products under Development by Companies
  13. Ovarian Cancer - Products under Investigation by Universities/Institutes
  14. Ovarian Cancer - Companies Involved in Therapeutics Development

For more information about this report visit http://www.researchandmarkets.com/research/m6lqgb/ovarian_cancer

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Women's Health, Ovarian Cancer Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Women's Health, Ovarian Cancer Drugs